Kairos Pharma Wins 2026 Healthcare Innovation Award for Drug Resistance Research

Kairos Pharma Ltd. (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches.

Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.

The recognition from GHP Magazine underscores the potential of Kairos Pharma’s approach to drug resistance, a major challenge in oncology. Drug resistance often limits the efficacy of standard therapies, leading to disease progression and relapse. By targeting CD105, ENV-105 could offer a new strategy to resensitize tumors to existing treatments, potentially improving outcomes for patients with prostate and lung cancers. The award may also raise awareness among investors and the broader medical community about the company’s pipeline, as noted in the press release available at https://ibn.fm/WuBOf.

Kairos Pharma, based in Los Angeles, California, continues to advance its clinical programs. The Phase 2 trial for castrate-resistant prostate cancer and Phase 1 trial for non-small cell lung cancer represent critical steps toward validating ENV-105’s safety and efficacy. If successful, the therapy could address significant unmet medical needs in cancers that have developed resistance to standard care. The company’s focus on structural biology provides a unique approach to identifying and targeting resistance mechanisms, differentiating it from other oncology companies.

Investors and stakeholders can find the latest news and updates regarding Kairos Pharma in the company’s newsroom at https://ibn.fm/KAPA. The award from GHP Magazine serves as an external validation of the company’s scientific strategy and its potential impact on cancer treatment.